FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of recombinant polypeptides of botulinum neurotoxin (hereinafter – BoNT); it can be used in medicine for the treatment of a condition related to undesired neuronal activity. BoNT polypeptides with a modified receptor-binding domain of Clostridium botulinum serotype B, strain 4 (B4-HC), having amino acid mutations, which modify binding of BoNT to human synaptotagmin II (hereinafter – Syt II), are proposed.
EFFECT: invention provides obtainment of BoNT polypeptides with enhanced binding to human Syt II.
44 cl, 24 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
| TREATMENT OF SKIN DISEASES | 2021 |
|
RU2840027C1 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| NON-TOXIC POLYPEPTIDES OF CLOSTRIDIAL NEUROTOXIN FOR USE IN TREATING NEUROLOGICAL DISORDERS | 2020 |
|
RU2839368C1 |
| MODIFIED BOTULINUM NEUROTOXIN FOR TREATING EXTREMITY SPASTICITY | 2021 |
|
RU2841585C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| CELLS HIGHLY SENSITIVE TO CLOSTRIDIAL NEUROTOXIN | 2020 |
|
RU2831112C2 |
